1. Home
  2. PIK3CA-Related Overgrowth Spectrum Doctors Near Me
  3. Clinical Trials
  4. A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers

PIK3CA-Related Overgrowth Spectrum Clinical Trials

Find PIK3CA-Related Overgrowth Spectrum Clinical Trials Near You

Find a DoctorCondition OverviewLatest AdvancesClinical TrialsTreatments

A Cohort Study to Identify Newer Therapeutic Targets in Head and Neck Cancers

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); 2. cell-cycle control (e.g., CDKN2A and CCND1); 3. cellular differentiation (e.g., NOTCH1); and 4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways. Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Histologically proven cases of primary head and neck cancers.

Locations
Other Locations
India
Banaras Hindu University
RECRUITING
Varanasi
Contact Information
Primary
Manoj Pandey, MS, PhD
manojpandey66@gmail.com
9336363640
Time Frame
Start Date: 2017-04-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 200
Treatments
Head neck cancer
Histologically diagnosed cases of head and neck cancer
Related Therapeutic Areas
PIK3CA-Related Overgrowth Spectrum
Sponsors
Leads: Banaras Hindu University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Who is this study for: Adult patients with metastatic or inoperable locally advanced triple negative breast cancer
Enrollment Status: Recruiting
Publish Date: March 16, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan
Study Phase: Phase 1/Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study

Enrollment Status: Recruiting
Publish Date: July 08, 2025
Intervention Type: Genetic, Drug
View All
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved